The Annals of pharmacotherapy
-
To evaluate the use of recombinant factor VIIa (rFVIIa) to reverse major bleeding from newer parenteral anticoagulant therapy. ⋯ rFVIIa may be considered to manage major refractory bleeding from newer parenteral anticoagulant agents when the benefit is thought to outweigh the thrombotic risk.
-
The benefits of inhaled corticosteroids (ICS) in reducing the mortality related to chronic obstructive pulmonary disease (COPD) are controversial. ⋯ ICS were found to be associated with a reduction in mortality rate when compared to LABA among patients with COPD. However, the ICS/LABA combination therapy did not provide any additional benefit on mortality when compared to ICS monotherapy.
-
Gastrointestinal (GI) adverse effects are common with oral opioid treatment. ⋯ The economic burden of GI events coincident with opioid treatment is significant for patients with a GI event recorded in claims. Reducing GI adverse effects has potential cost savings for the health-care system.
-
To review the current state of the science regarding intravenous fat emulsions (IVFEs), with an emphasis on their safety profile. ⋯ The results of this review demonstrate that IVFEs are well tolerated when administered in accordance with guideline recommendations.
-
To report a case of takotsubo cardiomyopathy, also known as apical ballooning syndrome or stress cardiomyopathy. ⋯ Takotsubo cardiomyopathy causes a reversible left ventricle dysfunction which occurs most commonly in postmenopausal women with or without cardiovascular disease. Recognition is detected with coronary angiography. It is thought to primarily be due to an abnormally high sympathetic stimulation after emotional or psychological stress. Treatment consists of an angiotensin-converting enzyme inhibitor and/or beta blocker if needed for left ventricular dysfunction and possibly an anxiolytic agent.